Biomarkers in Atopic Dermatitis and Psoriasis

BIOMAP examines the causes and mechanisms of atopic dermatitis and psoriasis by identifying the biomarkers responsible for the variation in disease outcome.

Taking advantage of recent technical developments in translational medicine, the project will enable drug discovery and improve direct disease management by combining clinical, genetic and epidemiological expertise with modern molecular analysis techniques and newly-developed tools in bioinformatics.

vision auge

Our Vision

BIOMAP aims to better define the heterogeneity and homogeneous aspects of atopic dermatitis and psoriasis and to develop new concepts for taxonomy and patient stratification.

BIOMAP Members

BIOMAP is a public-private partnership uniting 33 academic and industry partners from 13 countries to address key unmet needs in treating atopic dermatitis and psoriasis. Patient & Advisory Boards complement the expertise.

BIOMAP Timeline


Project start


Kick-off meeting, launch of website and Twitter account

Follow us on Twitter and LinkedIn.


BIOMAP Data and Analysis Portal launched


Two publications published in 2019


Novartis joins BIOMAP


University of Edinburgh joins BIOMAP


Five publications published in 2020


Almirall joins BIOMAP


BIOMAP Clip released

Watch our clip at the top of the page.


First lay summary published


BIOMAP Glossary published


IHI Mid-Term Review


Seven publications published in 2021



200 Twitter followers reached


Medical Center – University of Freiburg joins BIOMAP


Executive Management Team meets in Copenhagen


Two new lay summaries published, in total four available


Annual Consortium Meeting in Kiel


World Psoriasis Day 2022 and Website Relaunch


Ten publications published in 2022


Executive Management Team and Task Force Leaders meet in Frankfurt


IHI article on BIOMAP publication published: Examining data in new ways highlights genetic differences in psoriatic skin


Executive Management Team and Task Force Leaders meet in Frankfurt


Four new lay summaries published, in total eight available


End of project

Voices of BIOMAP

“By joining the expertise from academia and pharmaceutical industry, and by analysing a collection of harmonised clinical and molecular data from nearly a million sufferers, unprecedented in scale and depth, ranging from multi-dimensional datasets on single cells (skin and blood) through to whole populations, atopic dermatitis and psoriasis will be identified as a series of different diseases rather than just one disease, each with a characteristic molecular ‘signature’.”

Prof. Stephan Weidinger
Christian-Albrechts-Universität zu Kiel

“BIOMAP presents a major opportunity to improve the lives of people with skin disease – we need information on why and who is going to develop severe disease, and also new approaches to treatment. Involving a Patient Advisory Group puts the needs of the patients at the heart of the project from the very beginning. By providing a European-wide platform for collaboration, BIOMAP will enable sharing of know-how and data about atopic dermatitis and psoriasis so that we can all work together like never before.”

Helen McAteer
Chief Executive of the Psoriasis Association
BIOMAP Patient Advisory Group

“BIOMAP will help us to better understand the relationships between inherited susceptibility, environmental factors, and molecular profiles, as well as the roles of each of these in onset and progression of the diseases.”

Dr Witte Koopmann
Co-project lead
LEO Pharma

“The findings from BIOMAP will drive rapid drug discovery to target causal mechanisms, and will pinpoint biomarkers which can support clinicians to decide who, when and how to intervene.”

Professor Catherine Smith
King’s College London